The review’s central thesis is that atopic dermatitis itch emerges from a dynamic, bidirectional conversation between keratinocytes, the dominant cells of the epidermis, and the sensory neurons that innervate the skin. When the epithelial barrier breaks down, whether through genetic vulnerability, environmental insult, or the mechanical trauma of scratching, stressed keratinocytes release a cocktail of damage-induced mediators known as alarmins. Chief among these are thymic stromal lymphopoietin (TSLP), interleukin-33 (IL-33), and interleukin-25 (IL-25). These signals do not merely recruit immune cells; they act directly on cutaneous nerve fibers, activating or sensitizing them and thereby amplifying itch transmission. The result is a self-reinforcing itch-scratch-injury cycle in which each bout of scratching further damages the barrier, releases more pruritogens, and entrenches neural hypersensitivity.

TSLP has emerged as perhaps the clearest example of epithelial-to-neural signaling. This keratinocyte-derived cytokine signals through a receptor complex comprising the TSLP receptor and the IL-7 receptor alpha subunit, potently activating dendritic cells and skewing immunity toward a type 2 profile dominated by Th2 cells, mast cells, and natural killer T cells. Serum TSLP is significantly elevated in patients with atopic dermatitis and correlates with disease severity. Crucially, work by Wilson and colleagues showed that calcium-dependent ORAI1/NFAT signaling in keratinocytes regulates TSLP release, and that TSLP in turn directly activates TRPA1-positive sensory neurons to induce itch. The same epithelial-neuronal crosstalk operates in airway epithelial cells, suggesting a mechanistic bridge that may help explain the atopic march, the progression from eczema to asthma and allergic rhinitis.

IL-33 presents a more complicated picture. It induces type 2 cytokines including IL-4, IL-5, and IL-13, synergizes with IL-4 to drive production of IL-31, a key pruritogen, and enhances histamine-induced itch through mast cell activation and IL-13 release. Its receptor, ST2, is expressed on dorsal root ganglion neurons in both humans and mice, and IL-33 can sensitize these neurons to IL-4- and IL-13-mediated signaling. In the spinal cord, IL-33/ST2 signaling activates an astrocytic JAK2-STAT3 pathway that engages the gastrin-releasing peptide (GRP) axis, a canonical spinal itch circuit whose serum levels correlate with disease severity and itch intensity in patients. Yet the review is candid about the limits of the evidence: some studies found no correlation between circulating IL-33 and pruritus severity, and neuronal-restricted IL-33 receptor signaling proved dispensable for itch in an AD-like mouse model. Genetic variants in the IL33 gene have been linked to itch severity, hinting that predisposition modulates the pathway, but a direct causal role in human AD itch remains unproven.

The strongest clinical case belongs to the type 2 cytokines IL-4 and IL-13. Both can directly activate mouse and human sensory neurons, and IL-4 additionally sensitizes neurons to a broad range of pruritogens. Mechanistically, chronic itch requires neuronal IL-4Ralpha-JAK1 signaling: deleting IL-4Ralpha or JAK1 specifically in sensory neurons markedly reduces scratching in mice, and JAK inhibition relieves recalcitrant chronic itch in patients unresponsive to conventional immunosuppressants. Recent work with human dorsal root ganglion neurons showed that IL-4, IL-13, and IL-33 sensitize neurons to both histaminergic and non-histaminergic pruritogens within just two hours of exposure, with IL-4 and IL-13 inducing a shared, cytokine-specific transcriptional program distinct from that triggered by other inflammatory stimuli. Type 2 immunity, in other words, has been co-opted by the nervous system itself.

Interleukin-31 stands out as the most thoroughly validated cytokine linking immune activation to neuronal itch signaling. Produced mainly by Th2 cells but also by basophils, macrophages, and, as recent evidence shows, M2-polarized macrophages in lesional skin, IL-31 signals through a receptor complex of IL-31 receptor A and the oncostatin M receptor. In a restricted population of IL-31RA-positive, TRPV1-positive, TRPA1-positive sensory neurons, IL-31 triggers intracellular calcium release and ERK activation. It also induces rapid STAT3 activation in these neurons, and STAT3 transcriptionally upregulates the IL-31 receptor itself, creating a feed-forward loop that amplifies sensitivity. Beyond the periphery, IL-31 induces expression of B-type natriuretic peptide (BNP), encoded by the NPPB gene, which transmits itch signals through natriuretic peptide receptor A in the spinal cord, and promotes axonal elongation and branching in small-diameter sensory neurons, providing a mechanistic explanation for the increased cutaneous nerve fiber density seen in chronic disease. The clinically approved antibody nemolizumab targets this axis.

The review also highlights periostin, a matrix protein secreted by dermal fibroblasts downstream of type 2 inflammation, as a conserved pruritogen that induces itch across mice, dogs, and non-human primates. Periostin binds integrin alphavbeta3 on sensory neurons, triggering extracellular calcium influx and spontaneous firing in an itch-related, TRPV1- and TRPA1-dependent manner, with BNP as a key neuropeptide effector. Remarkably, periostin also reciprocally induces keratinocyte-derived TSLP through the JAK2-STAT3 pathway, closing a feed-forward epithelial-neuronal loop. Serum periostin levels are elevated in patients and correlate with disease severity, positioning it as an emerging therapeutic target.

Neurotrophic factors and neuropeptides add a structural dimension to the story. Nerve growth factor (NGF) is markedly elevated in the stratum corneum of lesional skin, correlating with itch severity, erythema, xerosis, eosinophil counts, and serum lactate dehydrogenase, and blocking NGF signaling ameliorates dermatitis and scratching in the NC/Nga mouse model. Substance P, classically acting through the neurokinin-1 receptor, drives neurogenic inflammation and correlates with itch intensity and even depression scores, but recent work shows it can also evoke non-histaminergic itch by activating MRGPRX2 on mast cells and MRGPRA1 on sensory neurons, and it has displayed paradoxically protective, barrier-restoring effects in some experimental settings. Calcitonin gene-related peptide (CGRP) promotes keratinocyte proliferation and epidermal thickening, with atopic keratinocytes showing heightened CGRP responsiveness and exaggerated hyperplasia. Artemin, a glial cell line-derived neurotrophic factor, is upregulated in lesional skin downstream of both the aryl hydrocarbon receptor, activated by organic components of air pollution, and toll-like receptor signaling triggered by house dust mite, linking environmental exposures directly to sensory nerve sprouting and warmth-provoked itch.

Woven through all of these pathways is the JAK-STAT signaling cascade, which the authors identify as the most clinically validated convergence point between immune cytokines and pruritus. Lesional skin from patients shows broad activation of phosphorylated JAK1-3 and STAT2/3 across epidermal and dermal compartments, and a spontaneous mouse model with an epidermal JAK1 gain-of-function mutation demonstrated that keratinocyte-intrinsic JAK1 hyperactivation alone is sufficient to drive barrier dysfunction, chronic inflammation, and pruritus. JAK1 is also enriched in pruriceptive neurons, where it mediates IL-4, IL-13, and IL-31 signaling, and electrophysiological studies suggest that JAK1-selective inhibitors such as upadacitinib can directly modulate cortical neuronal activity, hinting at central neuromodulatory effects beyond immune suppression.

The conceptual payoff of the review is a continuum model of chronic itch. It begins as peripherally driven, epithelial-mediated signaling, but repeated stimulation progressively sensitizes sensory neurons and broadens their responsiveness until itch becomes partially decoupled from peripheral cues and increasingly reflects structural and functional remodeling within itch-processing circuits. The finding that even non-lesional skin of patients exhibits heightened cowhage-induced itch underscores that altered sensory responsiveness is an intrinsic feature of the disease, not merely a byproduct of visible inflammation. The authors argue that early intervention to interrupt repetitive itch-scratch cycles, before central sensitization and neuronal remodeling become entrenched, may be essential to prevent long-term chronicity, treatment resistance, and the psychological comorbidities that so often shadow this disease.

Subject of Research: Neuroimmune mechanisms of chronic itch in atopic dermatitis

Article Title: Pruritogenic mediators in atopic dermatitis: mechanisms of neurogenic crosstalk

Article References: Wong, L.-S., Yang, J.-H., Yen, Y.-T., & Yang, J.-L. (2026). Pruritogenic mediators in atopic dermatitis: mechanisms of neurogenic crosstalk. Journal of Cutaneous Immunology and Allergy, 9, Article 16460. https://doi.org/10.3389/jcia.2026.16460

Image Credits: AI Generated

DOI: 10.3389/jcia.2026.16460

Keywords: atopic dermatitis, chronic itch, pruritus, keratinocytes, sensory neurons, TSLP, IL-31, IL-4, IL-13, JAK-STAT signaling, neuropeptides, neuroimmune crosstalk

The central surprise of the study lies in the asymmetry of this crosstalk. When the team exposed human monocytes and macrophages to TNF and IL-4 together, they expected the classic pattern of mutual cross-inhibition that has dominated the literature on antagonistic cytokine pairs. What they observed instead was cooperation. TNF functioned predominantly as a partner that expanded and intensified the set of genes switched on by IL-4, rather than as a brake. The interleukin’s own signature was not blunted by the presence of the inflammatory signal; it was broadened by it. This finding suggests that the anti-inflammatory cytokine does not merely survive contact with its proinflammatory counterpart but actively exploits TNF signaling to shape the scope of its own transcriptional output.

The selectivity of the reverse direction is equally striking. IL-4 did not shut down TNF signaling wholesale. Instead, it targeted a specific component of the TNF-induced program: the interferon response. Genes driven by interferon regulatory pathways, which form an important antimicrobial and immune-activating arm of TNF signaling, were selectively inhibited by IL-4. The broader inflammatory gene expression elicited by TNF, however, remained largely intact. In other words, IL-4 pruned the interferon branch of the TNF response while leaving the rest of the inflammatory tree standing. This level of precision implies that the two cytokines negotiate at the level of individual gene programs rather than through a simple global on-off switch.

Among the genes that responded synergistically to the combined cytokines were sets with well-recognized roles in regulating inflammation and promoting tissue repair. When TNF and IL-4 were present together, these gene sets were induced to levels far exceeding what either cytokine achieved alone. The synergy was not a minor quantitative effect confined to a handful of transcripts; it encompassed coordinated gene programs that shape how macrophages behave in damaged tissue. Because macrophages are central orchestrators of the transition from inflammation to repair, the identity of the genes governed by this combined signal carries weight for understanding how wounds progress from the inflammatory phase to the rebuilding phase.

To test whether this laboratory-scale crosstalk mattered in a living tissue context, the investigators turned to a skin wound-healing model. Their analysis revealed that the synergistically induced gene sets were highly expressed during precisely the phase of wound repair when TNF and IL-4 are co-expressed in the healing tissue. This temporal overlap is biologically meaningful. It suggests that the cooperative program observed in cultured human monocytes is not an artifact of the dish but reflects a naturally occurring transcriptional state in which the two cytokines act together in time and space. During the window when inflammation and repair must be balanced, the combined TNF and IL-4 signal appears to help define the macrophage phenotype that supports that balance.

Mechanistically, the study traced the crosstalk to epigenetic chromatin-mediated mechanisms rather than to changes in signaling alone. Transcription factors are the proteins that bind DNA and switch genes on, but whether they can reach their targets depends on the state of the chromatin, the packaged form of DNA in the cell. The researchers found that cooperation between NF-κB, the canonical transcription factor activated by TNF, and STAT6, the transcription factor activated downstream of the IL-4 receptor, underpinned the synergistic gene expression. Rather than acting through separate gene sets, these two pathways converged on shared regulatory elements, allowing a proinflammatory signal and an anti-inflammatory signal to jointly open and activate the same loci.

A second epigenetic mechanism involved the erasure of a repressive histone mark. Histone H3 lysine 27 trimethylation, abbreviated H3K27me3, is a chemical modification of chromatin that is generally associated with silenced or po genes held in a inactive state. In the presence of the combined cytokine signal, this negative mark was removed from relevant genomic regions, lifting a layer of repression and permitting transcriptional activation. The removal of H3K27me3 provides a plausible explanation for how the synergy produces gene induction that neither cytokine can accomplish alone: TNF signaling through NF-κB helps remodel the chromatin landscape in a way that makes IL-4-driven, STAT6-dependent transcription possible at genes that would otherwise remain closed.

The third mechanistic pillar was the selective inhibition of IRF1, a transcription factor that mediates interferon responses and contributes to the interferon arm of TNF signaling. By suppressing IRF1, IL-4 was able to disassemble the interferon component of the TNF program without dismantling TNF-driven inflammatory gene expression more broadly. This selective targeting helps explain the otherwise paradoxical combination of results: cooperation at repair-related and inflammation-regulating genes on one hand, and selective antagonism at interferon-responsive genes on the other. The crosstalk is therefore not a single mechanism but a coordinated set of chromatin-level events that produce different outcomes at different classes of target genes.

The authors frame these results as identifying a mechanism for the expansion of the IL-4 response, and the implications extend beyond basic cytokine biology. If TNF signaling is required for the full breadth of the IL-4 program in monocytes and macrophages, then broadly suppressing TNF, as many anti-TNF therapies do in conditions such as rheumatoid arthritis and inflammatory bowel disease, may have consequences that reach into the tissue-repair arm of immunity, not only the inflammatory arm. The study also highlights the complexity of crosstalk between antagonistic cytokines more generally, showing that pairs of signals long assumed to cancel each other out can instead cooperate on select gene responses that are important for immune function and tissue repair. Cross-inhibition, the traditional focus of the field, turns out to be only part of the story.

As with any study, the findings come with scope conditions worth keeping in view. The human cell work was performed in primary monocytes and macrophages, and the in vivo evidence comes from a skin wound-healing model, so extending the conclusions to other tissues, other disease settings, and other cytokine combinations will require further investigation. Nevertheless, the work offers a concrete and testable framework: antagonistic cytokines negotiate through transcription factor cooperation, targeted histone modification, and selective inhibition of intermediary factors such as IRF1. For a field that has long organized itself around the idea that inflammatory and anti-inflammatory signals are opponents, the demonstration that TNF can serve as a costimulator of the IL-4 program, and that the two jointly govern genes central to repair, is a reminder that the immune system’s wiring is built less on simple opposition than on context-dependent partnership.

Subject of Research: Crosstalk between the cytokines TNF and IL-4 in regulating gene expression in human monocytes and macrophages

Article Title: IL-4 exploits TNF signaling to shape its gene expression signature in monocytes and macrophages

Article References: Yuan, R., Yang, C., Mishra, B., Oliver, D., Bell, R. D., & Ivashkiv, L. B. (2026). IL-4 exploits TNF signaling to shape its gene expression signature in monocytes and macrophages. Nature Communications. https://doi.org/10.1038/s41467-026-78528-3

Image Credits: AI Generated

DOI: 10.1038/s41467-026-78528-3

Keywords: IL-4, TNF, monocytes, macrophages, cytokine crosstalk, NF-kB, STAT6, H3K27me3, IRF1, gene expression, wound healing, immunology

The EG95 protein has occupied a special place in echinococcosis research since its discovery as a protective antigen from oncosphere-stage parasites. Recombinant EG95-based vaccines have shown efficacy in sheep and have been deployed in some control programs, but the platform has persistent weaknesses. Protein subunit vaccines tend to elicit immune responses that wane relatively quickly, requiring booster doses and careful scheduling to maintain protection in flocks. Their production depends on expression systems that can be technically demanding, and the immunogenicity of the purified antigen, while real, is modest compared with what newer vaccine technologies can achieve. For a neglected zoonotic disease whose control depends on vaccinating large numbers of livestock in resource-limited settings, those limitations matter enormously.

The Chinese research group, whose members span institutions working on parasitic diseases and veterinary science, reasoned that the mRNA-lipid nanoparticle platform, which transformed human vaccinology during the COVID-19 pandemic, could address these shortcomings. mRNA vaccines instruct the recipient’s own cells to manufacture the target antigen, which means the protein is produced in its native form, with appropriate folding and post-translational modifications, and presented to the immune system in a context that engages both antibody and T-cell arms of immunity. The lipid nanoparticles that deliver the messenger RNA also act as built-in adjuvants, stimulating innate immune sensors that amplify the adaptive response. Manufacturing is fast, scalable, and does not require cell culture systems specific to each antigen, making the platform attractive for diseases that have never attracted the commercial investment of human medicine.

From this starting point, the team designed three vaccine candidates. The first was a straightforward EG95 mRNA-LNP vaccine, encoding the canonical protective antigen. The second, an IL-4-EG95 mRNA-LNP vaccine, was more inventive: it encoded a fusion protein in which EG95 was joined to interleukin-4, an immune signaling molecule, via a flexible peptide linker. The idea was to exploit the cytokine as a molecular adjuvant, tethering an immunostimulatory signal directly to the antigen so that cells taking up the vaccine would present EG95 in a context primed to enhance immune activation. The third candidate, an EG95-EC95 mRNA-LNP vaccine, took a multivalent approach, incorporating EC95 antigens derived from Echinococcus canadensis, a related parasite species within the E. granulosus sensu lato complex. Because the parasite species complex encompasses organisms with antigenic variation, a formulation that covers multiple variants could broaden protection across the range of parasites circulating in different regions and host species.

The researchers confirmed that all three vaccine candidates were efficiently encapsulated in lipid nanoparticles and that the encoded antigens were robustly expressed both in cell culture and in vaccinated animals. Expression of the target protein is the essential first step for any mRNA vaccine, and the fusion constructs, despite their added complexity, performed well. With the platform validated in vitro, the team moved to animal studies, comparing the mRNA vaccines head-to-head with a commercial EG95 subunit vaccine, the benchmark against which any new echinococcosis vaccine must be measured.

The immunological results were striking. In both mice and lambs, the mRNA-LNP vaccines induced humoral and cellular immune responses that were significantly stronger than those provoked by the subunit vaccine. Antibody titers rose higher and, critically, persisted longer: the animals maintained high levels of EG95-specific antibodies for more than twelve months after vaccination. For a livestock vaccine intended to protect animals through the period when they are most vulnerable to infection and through the breeding cycles of a working flock, that durability is a decisive advantage. It suggests that a vaccination schedule built on the mRNA platform could achieve with fewer doses what currently requires repeated boosters, reducing the logistical burden on herders and veterinary services in endemic regions.

Cellular immunity, often the neglected dimension in evaluations of antiparasitic vaccines, also differed markedly between the platforms. The mRNA vaccines engaged T-cell responses to a degree the subunit formulation did not match, a consequence of the way lipid nanoparticles deliver their cargo into cells and stimulate innate immune pathways. Because the immune response to Echinococcus involves both antibodies that attack oncospheres as they attempt to establish infection and cellular mechanisms that shape the environment around developing parasites, the breadth of the response induced by the mRNA platform may explain much of its protective superiority.

The decisive test came from parasite challenge experiments. When vaccinated animals were exposed to Echinococcus infection, the three mRNA-LNP vaccines all conferred protection, but the IL-4-EG95 fusion vaccine stood out. In animals receiving that formulation, the survival of protoscoleces, the larval forms that seed hydatid cysts, was inhibited, and the growth of cysts that did establish was suppressed. The fusion of the cytokine to the antigen, an approach that might have backfired by skewing immunity in an unhelpful direction, instead delivered the most effective protection of any candidate tested. The result validates the concept of genetically adjuvanted mRNA vaccines for parasitic diseases and suggests that the IL-4-EG95 construct is the leading candidate for further development.

The implications extend beyond echinococcosis itself. Cystic echinococcosis is one of many neglected zoonotic diseases for which the economics of vaccine development have never worked in favor of conventional platforms. The mRNA approach offers safety, scalability, and flexibility: the same lipid nanoparticle technology can be adapted to new antigens simply by changing the encoded sequence, and manufacturing does not depend on the biological quirks of expression systems. For a disease whose control requires coordinated vaccination of livestock, deworming of dogs, and public health surveillance across vast rural landscapes, a vaccine that is both more effective and longer-lasting could shift the calculus of elimination programs that have struggled for decades.

The study, published in PLOS Pathogens, positions EG95-based mRNA vaccines as a promising strategy for reducing the transmission of E. granulosus sensu lato and, with it, the zoonotic burden of cystic echinococcosis in the communities where the parasite remains endemic. Challenges remain before the platform reaches the field, including the regulatory pathways for veterinary mRNA vaccines, cold-chain requirements for lipid nanoparticle formulations, and the scale-up of challenge studies in livestock under natural transmission conditions. But the demonstration that mRNA vaccines can outperform the established subunit benchmark in both magnitude and duration of immunity, and that a cytokine-antigen fusion can push protection even further, gives researchers and control programs a concrete new tool to pursue. For a neglected disease that has waited decades for a technological leap, the arrival of one may finally be at hand.

Subject of Research: Development of EG95-based mRNA-lipid nanoparticle vaccines inducing long-term protective immunity against cystic echinococcosis

Article Title: Novel EG95-based mRNA vaccines induce long-term protective immunity against echinococcosis

Article References: Chen, W.-G., Li, L., Dai, G.-D., Wu, Y.-D., Zhu, C.-G., Zhang, H., Li, X.-R., Li, L., Zhang, N.-Z., Wang, L.-Q., Li, G.-C., Ma, W.-L., Pan, J.-T., Tan, M.-L., Da, F.-L., Yin, H., Fu, B.-Q., Luo, X.-N., Yan, H.-B., & Jia, W.-Z. (2026). Novel EG95-based mRNA vaccines induce long-term protective immunity against echinococcosis. PLOS Pathogens, 22(10), e1014659. https://doi.org/10.1371/journal.ppat.1014659

Image Credits: AI Generated

DOI: 10.1371/journal.ppat.1014659

Keywords: echinococcosis, Echinococcus granulosus, EG95, mRNA vaccine, lipid nanoparticles, zoonotic disease, veterinary vaccinology, humoral immunity, IL-4, parasitology, vaccine development, one health

The team, registered with PROSPERO and following PRISMA reporting guidelines, searched PubMed and the China National Knowledge Infrastructure through December 2025, ultimately distilling 106 retrieved records down to six eligible studies. To qualify, research had to involve patients aged sixty or older, measure inflammatory or inflammaging-related biomarkers in blood or skin, and quantify disease severity using validated instruments such as the SCORAD index. The methodological rigor extended to a deliberate sensitivity decision: one study that used squamous cell carcinoma antigen, a keratinocyte proliferation marker, as a laboratory surrogate for disease activity was retained in the primary synthesis but flagged, and its removal was tested to confirm the headline findings did not depend on it.

Statistically, the authors converted reported Pearson and Spearman correlation coefficients into Fisher’s z values, weighted them by sample size, and pooled them using DerSimonian-Laird random-effects models when heterogeneity demanded it. Four biomarker families survived the quantitative synthesis. Total IgE showed a moderate positive correlation with severity, pooled at r = 0.464 across 139 participants, and the estimate strengthened to r = 0.514 with minimal heterogeneity once the surrogate-based study was excluded. Eosinophil counts proved the most stable signal of all, correlating at r = 0.522 with essentially zero heterogeneity, suggesting these granulocytes remain a remarkably reliable barometer of eczema activity even in aged immune systems.

The cytokine story was messier and, arguably, more interesting. Interleukin-4, the canonical Th2 driver of allergic disease, correlated with severity at a pooled r = 0.571, but with a confidence interval stretching from 0.176 to 0.808 and heterogeneity approaching 87 percent. Interleukin-17, representing the Th17 axis, landed at a similar pooled r = 0.566 with nearly identical heterogeneity. In a younger population, such statistical noise might be dismissed as methodological artifact. Here, the authors argue, it may be a genuine biological signal: some elderly patients appear to run a Th2-high profile familiar from pediatric eczema, while others shift toward a Th17-dominant or mixed phenotype, a divergence that could explain why biologic therapies targeting a single pathway produce such variable results in older adults.

To organize this complexity, the researchers proposed a four-stage conceptual framework, explicitly labeled hypothesis-generating rather than proven. The first stage is inflammaging itself: the chronic, low-grade elevation of pro-inflammatory mediators that accompanies immunosenescence. In one cohort of 21 patients, the inflammaging markers IL-6, CXCL1, CCL7, and SELE all correlated significantly with severity, with coefficients between 0.45 and 0.54. The idea is that this systemic inflammatory backdrop lowers the threshold for skin immune homeostasis, priming the tissue to overreact to triggers that a younger immune system would quietly tolerate. Inflammaging, in this model, is not merely a bystander but the catalyst that sets the entire cascade in motion.

The second stage describes an abnormally amplified Th2 response operating within that inflamed terrain. Across six studies and 243 patients, the Th2 cluster, including IL-4, TSLP, TARC, CCL26, eosinophils, and total IgE, showed correlations ranging from 0.10 to 0.79, with ten of twelve individual associations reaching significance. The internal inconsistency is telling. Eosinophils tracked severity faithfully, while IgE performed erratically, echoing observations that late-onset atopic dermatitis frequently presents as an intrinsic variant with lower IgE and atypical inflammatory profiles. Some patients may retain the classic Th2 signature; others may drift toward what the authors call a Th2-evolved pattern, in which IL-4 signals wane and cytokines like IL-13 or IL-31 take over the driver’s seat.

Stage three introduces the Th17 axis as an aberrant intruder. In healthy immune regulation, Th17 activity is held in check by counterbalancing networks, but aging is known to disturb the Th17/Treg balance. The pooled data, drawing on IL-17, IL-17A, IL-17C, IL-22, and CCL20 across three studies, showed moderate-to-strong correlations with severity, with individual coefficients spanning 0.32 to 0.76. The authors hypothesize that weakened regulatory constraints in the aged immune system allow this normally secondary pathway to run amok in a subset of patients, producing a Th17-high endophenotype. If validated in prospective, molecularly stratified cohorts, this could reshape therapeutic thinking, since IL-17 and IL-23 blockers may benefit one subgroup of elderly patients while doing little for another.

The final stage is where the disease becomes self-sustaining. Tissue remodeling markers, matrix metalloproteinase 12, ezrin, and cadherin 3, showed the strongest correlations with severity of any group, ranging from 0.56 to 0.59, all highly significant. MMP12 in particular sits at the junction between immune inflammation and structural collapse: its upregulation drives extracellular matrix degradation and disrupts keratinocyte differentiation, breaching the skin barrier and feeding the very inflammation that produced it. This inflammation-barrier destruction vicious cycle, the authors contend, is the molecular engine of chronicity, explaining the refractory, non-healing lesions that clinicians so often see in older patients regardless of which immune pathway dominates upstream.

The clinical implications are significant. Treatment decisions in elderly eczema, the authors emphasize, must weigh biological age, frailty, and immunosenescence status rather than severity scores alone. Age-specific evidence for biologics remains thin, though promising case data exist for dupilumab, the IL-4/IL-13 blocker, even in patients over eighty. If biomarker-defined subgroups can be validated, the four-stage framework could eventually guide which older patients get Th2-targeted agents, which need Th17 coverage, and which require barrier-restoration strategies to break the remodeling cycle. That vision, however, remains aspirational.

The authors are candid about the limits of their evidence. Only four biomarkers were formally pooled; most contributed just two to four effect sizes, too few for funnel plots, Egger’s tests, or meaningful meta-regression. The included studies were overwhelmingly cross-sectional, so causality and temporal sequence cannot be established, and the search was confined to two databases. Small samples, inconsistent confounder control, and methodological variation likely inflate the heterogeneity figures. The four-stage model is therefore a scaffold for future research, not a settled pathway. Even so, the message is hard to ignore: as populations age worldwide, eczema in the elderly is rising, and it may demand its own immunology, its own biomarkers, and its own playbook, rather than a pediatric disease map stretched over older skin.

Subject of Research: Immune axis imbalance and inflammaging mechanisms underlying chronic atopic dermatitis in elderly patients

Article Title: Inflammatory Aging‐Driven Immune Axis Imbalance and the Mechanisms of Chronicity in Elderly Atopic Dermatitis: A Systematic Review and Meta‐Analysis

Article References: Wu, N., Li, Y., Wang, X., Wu, Y., & Yin, W. (2026). Inflammatory Aging‐Driven Immune Axis Imbalance and the Mechanisms of Chronicity in Elderly Atopic Dermatitis: A Systematic Review and Meta‐Analysis. Immunity, Inflammation and Disease, 14(9), Article e70528. https://doi.org/10.1002/iid3.70528

Image Credits: AI Generated

DOI: 10.1002/iid3.70528

Keywords: atopic dermatitis, inflammaging, immunosenescence, meta-analysis, Th2 response, Th17 axis, IL-17, IL-4, eosinophils, MMP12, skin barrier, elderly patients

The findings, published in BMC Biology, connect population genetics with clinical infectious-disease research. The investigators examined the evolutionary history of IL-4, TLR2, CCL2 and SLC11A1, genes involved in regulating inflammation and the detection or control of invading pathogens. They then compared genetic variation in these genes with clinical outcomes among nearly 4,000 people in Italy who had tested positive for SARS-CoV-2 through the Italian GEN-COVID study.

The evolutionary analysis used genetic data from more than 2,000 individuals representing African, European and Asian populations. The researchers searched for patterns consistent with natural selection, including differences in allele frequencies between populations and other signatures indicating that particular genetic variants had been favored or removed over time. All four genes showed evidence of evolutionary change, although the patterns differed across regions. That variation suggests that infectious diseases and other environmental pressures have shaped immune responses along distinct population histories.

Natural selection can act on immune genes in complex ways. A variant that improves resistance to one pathogen may increase the risk of excessive inflammation or another disease under different conditions. Immune genes are therefore often subject to balancing pressures rather than a single, universally beneficial genetic solution. The study’s results indicate that the versions of these genes common today may reflect long-term compromises between pathogen defense, inflammatory damage and changing environments.

The researchers also compared modern human sequences with genetic material from Neanderthals and Denisovans, extinct relatives of modern humans. Some shared variants may have been inherited from a common ancestor, while others could reflect interbreeding between ancient modern humans and these archaic populations. Such exchanges introduced genetic material into ancestral human populations tens of thousands of years ago, potentially including immune-related variants that influenced how later generations responded to infectious organisms.

These evolutionary signatures were established long before SARS-CoV-2 appeared. The coronavirus did not create the ancient patterns detected in the four genes; instead, it encountered immune systems already shaped by earlier infectious threats. “SARS-CoV-2, the coronavirus that causes COVID-19, may be new, but the immune system it encountered isn’t,” said Michael Campbell, an associate professor of biological sciences at USC Dornsife and the study’s senior author. The distinction is important because it frames COVID-19 susceptibility as a possible consequence of pre-existing biological variation rather than a response that evolved during the pandemic.

The clinical analysis produced a more recent and specific finding involving TLR2, which encodes Toll-like receptor 2. TLR2 is part of the innate immune system, the body’s rapid first line of defense against infection. It recognizes molecular patterns associated with microbes and activates signaling pathways that stimulate inflammatory responses. Two rare TLR2 variants were identified in the Italian COVID-19 dataset. One occurred more frequently among patients who had previously received organ transplants, while the other was associated with more severe COVID-19.

The transplant-related observation is notable because organ-transplant recipients already face elevated risks from COVID-19. Immunosuppressive medications used to prevent rejection can weaken antiviral defenses, while the underlying medical conditions of recipients may further increase vulnerability. A rare alteration in TLR2 could potentially add another layer of risk by changing pathogen recognition or downstream inflammatory signaling. However, the study does not establish that either variant causes severe disease, and the observed associations may be influenced by sample size, population structure or other clinical factors.

The researchers emphasize that the TLR2 results require replication in larger and more genetically diverse groups. Rare variants are particularly difficult to evaluate because they occur infrequently, meaning that even a study involving thousands of participants may contain only a small number of carriers. Independent cohorts, functional laboratory experiments and mechanistic studies will be needed to determine whether the variants alter TLR2 expression, protein activity or immune signaling during SARS-CoV-2 infection. Broader sampling will also help clarify whether the associations apply beyond the Italian population.

By combining evolutionary genomics with patient data, the study illustrates how ancient genetic history can guide investigations of modern viral disease. Genes shaped by past pathogens may contain clues to why individuals respond differently to the same infection, while rare mutations can reveal additional vulnerabilities that are invisible when researchers focus only on common variation. The authors say that this approach could eventually identify biological pathways useful for predicting disease risk or developing new preventive and therapeutic strategies, although such applications remain a future possibility rather than an immediate clinical outcome.

Subject of Research: People

Article Title: The evolutionary landscape of host immunity genes involved in respiratory and other immune-related diseases, and the identification of TLR2 variation associated with severe COVID-19

News Publication Date: 29-May-2026

Web References: https://doi.org/10.1186/s12915-026-02623-6

References: BMC Biology, DOI: 10.1186/s12915-026-02623-6

Keywords: COVID-19, SARS-CoV-2, TLR2, immune genes, evolutionary genetics, natural selection, rare genetic variants, severe disease, organ transplantation, infectious diseases